Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 253 of 6351
-
New drug cocktail aims to stop bile duct cancer from returning after surgery
Disease control OngoingA randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative recurrence-free survival. In this study, we aim …
Phase 2/3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:52 UTC
-
Couples therapy takes on suicide: a new approach targets both emotions and relationships
Symptom relief CompletedSelf-injurious thoughts and behaviors (SITBs), including suicide, thinking about suicide, and self-injury without intent to die, are major public health crises, with variably effective, and sometimes long and expensive, interventions. SITBs are particularly common in borderline p…
Sponsor: York University • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Can a laser beam silence chronic vulvar pain?
Symptom relief OngoingThe study aims to assess the efficacy, acceptance and safety profile of vulvovaginal laser therapy in women with vulvodynia.
Sponsor: Medical University of Graz • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Promising new combo tackles melanoma brain metastases in phase 2 trial
Disease control Recruiting nowThis phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells …
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC
-
New cocktail of drugs and radiation takes on tough lung cancer
Disease control OngoingThis phase I/II trials investigates the side effects of olaparib and durvalumab and how well it works in combination with carboplatin, etoposide, and/or radiation therapy in treating patients with extensive stage-small cell lung cancer (ES-SCLC) who have not received treatment fo…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to beat back tough lymphoma
Disease control Recruiting nowThis phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). T cells a…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug shows promise for rare HER2-Mutated cancers
Disease control OngoingThis is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are pati…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo could cut malaria risks in pregnancy
Prevention CompletedThis trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) + dihydroartemisin-piperaquine (DP) will significantly reduce the risk of adverse birth outcomes compared to IPTp with SP alone or DP alone. This double-…
Phase 3 • Sponsor: Grant Dorsey, M.D, Ph.D. • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
A sharper MRI could reveal radiation sensitivity of brain tumors
Diagnosis CompletedStereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen …
Sponsor: Lund University Hospital • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Immunotherapy shows promise for tough brain cancers
Disease control OngoingThis phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes (mutations) to genes that control the w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New combo therapy shows promise against advanced melanoma before surgery
Disease control CompletedThis is a Phase 2 open-label, single-arm study of neoadjuvant treatment of intratumoral tavo-EP plus nivolumab IV infusion. Eligible participants will be those with pathological diagnosis of operable locally-regionally advanced melanoma.
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo therapy aims to outsmart relapsed leukemia in kids
Disease control Recruiting nowThis phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a tiny device fix a leaky heart valve without Open-Heart surgery?
Disease control OngoingThe objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System in the treatment of patients with severe degenerative mitral regurgitation (DMR).
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a monthly shot beat daily pills for fentanyl users?
Disease control CompletedThe study is 12-week, randomized, open-label study comparing injectable extended-release buprenorphine (Sublocade) to standard therapy (sublingual buprenorphine), to see if Sublocade will be more helpful in treating opiate use for individuals testing positive for fentanyl and rel…
Phase 2 • Sponsor: Frances R Levin • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New pill could help people with low platelet disorder
Disease control OngoingThis was a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of \<30,000/μL (and no single platelet count \>35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients rec…
Phase 3 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug aims to slow kidney failure in common kidney disease
Disease control OngoingThe ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy targets breast cancer in the brain and spine
Disease control OngoingThe purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which has metastasized to the leptomeninges.
Phase 1/2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cocktail aims to outsmart lung cancer resistance
Disease control OngoingThis is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Phase 2/3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Targeted drug combo aims to tackle Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a to…
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Chinese COVID-19 vaccine trial shows strong immune response in 960 volunteers
Vaccine CompletedThis was a phase II, randomized, placebo-controlled, observer-blinded study of the safety and immunogenicity of SARS-CoV-2 messenger RNA (mRNA) vaccine (BNT162b2) in Chinese healthy population. After randomization, the trial for each participant lasted for approximately 13 months…
Phase 2 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 11:03 UTC